Advertisement


Shilpa Gupta, MD, on Locally Advanced/Metastatic Urothelial Cancer: Phase III MAIN-CAV Trial

ASCO 2026

Advertisement

Shilpa Gupta, MD, of Taussig Cancer Institute, discusses findings from the phase III MAIN-CAV study (Alliance A032001) of maintenance cabozantinib and avelumab vs avelumab after first-line platinum-based chemotherapy in patients with locally advanced/metastatic urothelial cancer (Abstract 4514).



Related Videos

Gynecologic Cancers

Linda R. Mileshkin, MD, MBBS, FRACP, on Puxitatug Samrotecan for Endometrial or Ovarian Cancer

Linda R. Mileshkin, MD, MBBS, FRACP, of Peter MacCallum Cancer Centre, shares results from the phase I/IIA BLUESTAR study on the safety and efficacy of puxitatug samrotecan, a B7-H4–directed topoisomerase I inhibitor antibody-drug conjugate, in patients with endometrial cancer or ovarian cancer (Abstract 5515). 

Jennifer J. Knox, MD, FRCPC, on RASolute 302 Findings: Expert Point of View

Jennifer J. Knox, MD, FRCPC, of Princess Margaret Cancer Centre, provides expert commentary on a phase III study of daraxonrasib vs chemotherapy in previously treated metastatic pancreatic cancer (Abstract LBA5).

Lymphoma

Dai Chihara, MD, on a Regimen for Older, Unfit, or Frail Patients With Newly Diagnosed DLBCL

Dai Chihara, MD, of The University of Texas MD Anderson Cancer Center, reviews results from an open-label, single-arm, phase II trial that investigated the combination of epcoritamab with R-miniCVP (rituximab, cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) classified as unfit or frail per geriatric assessment or not eligible for anthracycline chemotherapy due to reduced ejection function or prior exposure (Abstract 7002). 

Skin Cancer

Evan T. Hall, MD, on Merkel Cell Carcinoma: Tuvusertib With or Without Avelumab

Evan T. Hall, MD, of Fred Hutchinson Cancer Center, discusses findings from the randomized phase II MATRiX trial, which evaluated the efficacy of the ATR inhibitor tuvusertib with or without avelumab in patients with anti–PD-(L)1–refractory Merkel cell carcinoma (Abstract LBA9514).

Skin Cancer

Danny Rischin, MD, on Adjuvant Cemiplimab for High-Risk CSCC

Danny Rischin, MD, of Peter MacCallum Cancer Centre, talks about data from the disease-free survival analyses of the C-POST study, which were conducted per high-risk criteria and start time after radiotherapy. C-POST evaluated adjuvant cemiplimab-rwlc for patients with high-risk cutaneous squamous cell carcinoma (CSCC) (Abstract 6083).

Advertisement

Advertisement




Advertisement